Document is current
Any future updates will be listed below
-
Authors
Mäki-Nevala, Satu
Kauppinen, Anni
Olkinuora, Alisa
Laiho, Aleksi
Törönen, Petri
Renkonen-Sinisalo, Laura
Lepistö, Anna
Seppälä, Toni T.
Mecklin, Jukka-Pekka
Peltomäki, Päivi
-
Funding
Funding for this research was provided by:
Research Council of Finland (331284, 357350, 330606)
Biomedicum Helsinki-säätiö
Syöpäsäätiö
Sigrid Juséliuksen Säätiö
Jane ja Aatos Erkon Säätiö
University of Helsinki
- License Information
-
More Information
Article History
Received: 16 April 2024
Accepted: 9 July 2025
First Online: 2 August 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. All biopsies were taken after patients’ informed consent. The study was approved by the Institutional Review Boards of the Central Finland Health Care District (Dnro 10U/2011, 3.5.2011) and the Helsinki and Uusimaa Health Care District (HUS/390/2021, 23.2.2022).
: Not applicable.
: T.T.S. reports consultation fees from Amgen Finland, Tillots Pharma and Nouscom, being a co-owner and CEO of Healthfund Finland Ltd, and a position in the Clinical Advisory Board and a minor shareholder of Lynsight Ltd. P.P. reports a position in the Clinical Advisory Board of Lynsight Ltd. The other authors declare that they have no competing interests.
